Effect of Baxdrostat on Cortisol Responsiveness in Hypertension: Phase 2 Results
A ldosterone synthase inhibitors have demonstrated efficacy in lowering blood pressure in patients with difficult-to-control hypertension.1-3 Early aldosterone synthase inhibitors lacked specificity for aldosterone synthase (via the CYP11B2 gene) over its close homolog cortisol synthase (via the CYP11B1 gene), leading to suppressed adrenal cortisol production.4 Drug-induced cortisol insufficiency has not been detected in trials of highly selective aldosterone synthase inhibitors.1-5 We report the effect of 8-week exposure to baxdrostat on cortisol levels after stimulation with adrenocorticotropic hormone in patients with uncontrolled hypertension. METHODS
Authors
- Shira Perl
- Bryan Williams (ORCID: https://orcid.org/0000-0002-8094-1841)
- Michel Azizi (ORCID: https://orcid.org/0000-0003-0597-8318)
- Naomi D.L. Fisher (ORCID: https://orcid.org/0000-0003-1649-1441)
- Hirotaka Shibata (ORCID: https://orcid.org/0000-0001-6506-4820)
- Aina S. Lihn
- Wunan Zhou (ORCID: https://orcid.org/0000-0003-0731-9287)
- Xingyu Li (ORCID: https://orcid.org/0009-0008-2354-2538)
Institutions
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Oita University (JP)
- Université Paris Cité (FR)
- National Institute for Health and Care Research (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- UCL Biomedical Research Centre (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Centre d'Investigation Clinique Hôpital Européen Georges Pompidou (FR)
- University College London (GB)
Publication Details
- Journal
- Hypertension
- Published
- 2026-10-27
- DOI
- https://doi.org/10.1161/hypertensionaha.126.27743
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca